Journal
IMMUNOLOGIC RESEARCH
Volume 45, Issue 1, Pages 85-95Publisher
HUMANA PRESS INC
DOI: 10.1007/s12026-009-8114-9
Keywords
Glioma; Glioblastoma; Immunotherapy; T cell; gamma delta T cell; Innate immunity
Categories
Funding
- National Institutes of Health NCI [P50 CA 097247-06A1]
- NINDS [R21 NS057431-01A1]
- Brain Tumor Society Samuel Gershon Leadership Chair
Ask authors/readers for more resources
Almost all individuals diagnosed with glioblastoma multiforme (GBM) will die of their disease as no effective therapies exist. Clearly, novel approaches to this problem are needed. Unlike the adaptive alpha beta T cell-mediated immune response, which requires antigen processing and MHC-restricted peptide display by antigen-presenting cells, gamma delta T cells can broadly recognize and immediately respond to a variety of MHC-like stress-induced self antigens, many of which are expressed on human GBM cells. Until now, there has been little progress toward clinical application, although several investigators have recently published clinically approvable methods for large-scale ex vivo expansion of functional gamma delta T cells for therapeutic purposes. This review discusses the biology of gamma delta T cells with respect to innate immunotherapy of cancer with a focus on GBM, and explores graft engineering techniques in development for the therapeutic use of gamma delta T cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available